Metrics of salbutamol use as predictors of future adverse outcomes in asthma

Beta‐agonist overuse is associated with adverse outcomes in asthma, however, the relationships between different metrics of salbutamol use and future risk are uncertain.

[1]  D. Shaw,et al.  Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. , 2013, The Lancet. Respiratory medicine.

[2]  D. Shaw,et al.  Use of metered-dose inhaler electronic monitoring in a real-world asthma randomized controlled trial. , 2013, The journal of allergy and clinical immunology. In practice.

[3]  R. Beasley,et al.  Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: implications for asthma clinical trial use. , 2012, Journal of Allergy and Clinical Immunology.

[4]  L. Boulet,et al.  Adherence: the goal to control asthma. , 2012, Clinics in chest medicine.

[5]  P. Donnan,et al.  Patient, practice and organisational influences on asthma control: observational data from a national study on primary care in the United Kingdom. , 2012, International journal of nursing studies.

[6]  S. Szefler,et al.  Evaluation of the National Heart, Lung, and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations. , 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[7]  Urs Frey,et al.  Predicting future risk of asthma exacerbations using individual conditional probabilities. , 2011, The Journal of allergy and clinical immunology.

[8]  E. Bleecker,et al.  Subacute Lack of Asthma Control and Acute Asthma Exacerbation History as Predictors of Subsequent Acute Asthma Exacerbations: Evidence From Managed Care Data , 2010, The Journal of asthma : official journal of the Association for the Care of Asthma.

[9]  I. Pavord,et al.  An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. , 2009, American journal of respiratory and critical care medicine.

[10]  Neil Pearce,et al.  The use of beta agonists and the risk of death and near death from asthma. , 2009, Journal of clinical epidemiology.

[11]  I. Pavord,et al.  A new perspective on concepts of asthma severity and control , 2008, European Respiratory Journal.

[12]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[13]  David M. Shade,et al.  Predicting episodes of poor asthma control in treated patients with asthma. , 2006, The Journal of allergy and clinical immunology.

[14]  Guillermo Mendoza,et al.  The controller-to-total asthma medication ratio is associated with patient-centered as well as utilization outcomes. , 2006, Chest.

[15]  N. Zamel,et al.  Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. , 2006, Chest.

[16]  Linda Abetz,et al.  Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. , 2006, Respiratory medicine.

[17]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[18]  A David Paltiel,et al.  A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. , 2004, Chest.

[19]  R. Beasley,et al.  The use of the self-management plan system of care in adult asthma. , 2004, Primary care respiratory journal : journal of the General Practice Airways Group.

[20]  T. Lieu,et al.  Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. , 2001, The European respiratory journal.

[21]  G H Guyatt,et al.  Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.

[22]  N. Pearce,et al.  Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? , 1999, The Journal of allergy and clinical immunology.

[23]  D. Cockcroft,et al.  Risk factors for death from asthma. Prairie Provinces Asthma Study Group. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[24]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[25]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[26]  C. Ulrik,et al.  Mortality and markers of risk of asthma death among 1,075 outpatients with asthma. , 1995, Chest.

[27]  S. Suissa,et al.  Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. , 1994, The European respiratory journal.

[28]  N. Pearce,et al.  A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. , 1993, The European respiratory journal.

[29]  C. Rand,et al.  Metered-dose inhaler adherence in a clinical trial. , 1992, The American review of respiratory disease.

[30]  N. Pearce,et al.  The self-administration of inhaled beta agonist drugs during severe asthma. , 1990, The New Zealand medical journal.